Mainz Biomed B.V. (MYNZ)
| Market Cap | 13.61M |
| Revenue (ttm) | 895,479 |
| Net Income (ttm) | -26.30M |
| Shares Out | 21.89M |
| EPS (ttm) | -1.62 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 120,798 |
| Open | 0.641 |
| Previous Close | 0.674 |
| Day's Range | 0.611 - 0.705 |
| 52-Week Range | 0.600 - 6.000 |
| Beta | 0.28 |
| Analysts | Buy |
| Price Target | 3.00 (+382.24%) |
| Earnings Date | May 28, 2024 |
About MYNZ
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany. [Read more]
Financial Performance
In 2023, MYNZ's revenue was $895,479, an increase of 69.00% compared to the previous year's $529,877. Losses were -$26.30 million, -0.35% less than in 2022.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for MYNZ stock is "Buy." The 12-month stock price forecast is $3.0, which is an increase of 382.24% from the latest price.
News
Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial
Mainz Biomed Presented Industry Leading Results: 97% Sensitivity for Colorectal Cancer, 82% for Advanced Precancerous Lesions The eAArly DETECT results demonstrated that within the advanced precancero...
Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.
BERKELEY, Calif. and MAINZ, Germany, May 07, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic
Groundbreaking topline results demonstrated sensitivity for colorectal cancer of 92% with specificity of 90% and best-in-class sensitivity for advanced adenoma of 82% 690 subjects analyzed including p...
Mainz Biomed Reports Full Year 2023 Financial Results
BERKELEY, Calif. and MAINZ, Germany, April 09, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment
BERKELEY, Calif. and MAINZ, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options
BERKELEY, Calif. and MAINZ, Germany, March 18, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations
BERKELEY, Calif. and MAINZ, Germany, March 12, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic
Dr. Jay Wohlgemuth, former Chief Medical & Scientific Officer of Quest Diagnostics and Dr. Ray Tabibiazar, a seasoned industry executive, to lead collaboration Mainz Biomed's Pivotal FDA PMA clinical ...
Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community
BERKELEY, Calif. and MAINZ, Germany, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert®
BERKELEY, Calif. and MAINZ, Germany, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy
BERKELEY, Calif. and MAINZ, Germany, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed Establishes Physician-Led Laboratory Expanding Service Offering for Privately Insured Patients in Germany
BERKELEY, Calif. and MAINZ, Germany, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium
BERKELEY, Calif. and MAINZ, Germany, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed Provides Year-End Corporate Review 2023
European Study ColoFuture and U.S. Study eAArly DETECT report sensitivity and specificity for the detection of Colorectal Cancer and Advanced Adenoma exceeding competition ReconAAsense designed to eva...
Is This BioTech Play Severely Undervalued? BioTech Shares Promising Results From Colorectal Study
Mainz Biomed N.V. MYNZ recently released the results of its ColoFuture study in the American healthcare market.
Mainz Biomed and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for Employees
BERKELEY, Calif. and MAINZ, Germany, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed Showcases ColoAlert® at Two Prominent Gastroenterology Conferences in Poland
BERKELEY, Calif. and MAINZ, Germany, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed Reports Positive Topline Results from U.S. eAArly DETECT Study Evaluating Novel mRNA Biomarkers
Groundbreaking Results Demonstrate Sensitivity for Colorectal Cancer of 97% with Specificity of 97% and Advanced Adenoma Sensitivity of 82% Results Exceed those from the Company's European ColoFuture ...
Mainz Biomed's Presentation at the 35th Annual Piper Sandler Healthcare Conference to be Made Available via Webcast
BERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed to Present at the 35th Annual Piper Sandler Healthcare Conference
BERKELEY, Calif. and MAINZ, Germany, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed Reports Third Quarter 2023 Financial Results and Provides Corporate Update
ColoAlert® Revenue Increases 102% Year Over Year for the Nine Months Ended September 30, 2023 ColoFuture Study Reported Groundbreaking Results Demonstrating Sensitivity for Colorectal Cancer of 94% wi...
Mainz Biomed Announces Closing of $5.0 million Registered Direct Offering
BERKELEY, Calif. and MAINZ, Germany, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed Announces Pricing of $5.0 million Registered Direct Offering
BERKELEY, Calif. and MAINZ, Germany, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed Partners with Liquid Biosciences to Harness the Power of Artificial Intelligence (AI) to Develop Next-generation Colorectal Screening Test
Mainz Biomed Partners with Liquid Biosciences to Harness the Power of Artificial Intelligence (AI) to Develop Next-generation Colorectal Screening Test
Mainz Biomed to Showcase ColoAlert® at Leading Global Healthcare Event, MEDICA
BERKELEY, Calif. and MAINZ, Germany, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.